Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.59 USD

87.59
5,119,705

-1.18 (-1.33%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $87.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

Is Labcorp Stock a Good Pick for Your Portfolio Right Now?

Investors are increasingly optimistic about LH due to its partnerships and operational discipline.

Should You Retain Hologic Stock in Your Portfolio Now?

HOLX's strength in the Molecular Diagnostics wing instills optimism among investors. Yet, macro woes and currency impacts raise concerns.

Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock

NEOG faces intense competition resulting from competitors' development of new technologies, which could affect the marketability and profitability of its products.

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS stores nationwide.

IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant

According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs.

Mark Vickery headshot

Top Analyst Reports for UnitedHealth, Bank of America & SAP

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Bank of America Corporation (BAC) and SAP SE (SAP).

QGEN Collaborates With McGill University Centre: Stock to Gain?

QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health.

Expanding Global Market, NuVasive Benefits to Aid GMED Stock

Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours

ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.

Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain?

LH launches new enhancements to Global Trial Connect to streamline site workflow.

Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?

DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.

National Vision Q3 Earnings Top Estimates, Revenues Lag, Stock Tumbles

EYE's third-quarter 2024 results reflect ongoing strength in Managed Care, with growth in America's Best stores.

INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up

Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.

ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues

Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace.

Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand

HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025.

OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts

Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.

AMN Stock Falls Despite Q3 Earnings & Revenues Beat, Margins Contract

AMN Healthcare's dismal results in the majority of its segments led to a soft overall third-quarter performance.

PBH Q2 Earnings Match Estimates, Revenues Beat, Shares Rise

Prestige Consumer Healthcare's second-quarter sales are impacted by the ongoing supply chain challenges in the Clear Eyes business.

CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised

Clover Health's third-quarter 2024 results continue to benefit from the strength of its business model.

Urmimala Biswas headshot

Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy?

Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic.

Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

BDX Stock Gains Following Q4 Earnings Beat and Higher Margins

BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments.

QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up

QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.

Phibro's Q1 Earnings Top Estimates, Stock Up, Net Sales Surge Y/Y

PAHC delivers strong growth across all its segments in the first quarter of fiscal 2025.

Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall

CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.